Navigation Links
FDA Approves Combo Shot for Meningitis, Hib in Kids
Date:6/15/2012

FRIDAY, June 15 (HealthDay News) -- A new combination vaccine that protects children against two potentially deadly bacterial diseases has been approved by the U.S. Food and Drug Administration.

The Menhibrix vaccine is for children ages 6 weeks to 18 months and guards against the bacteria Neisseria meningitidis (meningococcal disease, including bacterial meningitis) and Haemophilus influenzae type b (Hib disease).

These bacteria can cause sepsis by infecting the bloodstream and can cause meningitis by infecting the lining that surrounds the brain and spinal cord. Diseases caused by these bacteria often progress rapidly and can cause death or serious, long-term problems such as blindness, mental retardation or amputations, according to background information provided in an FDA news release.

Early symptoms for both meningococcal and Hib diseases can be difficult to distinguish from other common childhood illnesses, the experts noted.

The FDA approval is based on studies that assessed the effectiveness of the vaccine in several hundred U.S. infants and toddlers and tested the safety of the vaccine in about 7,500 infants and toddlers in the United States, Mexico and Australia.

Common negative side effects included pain, redness and swelling at the injection site, as well as irritability and fever.

Menhibrix is given as a four-dose series at 2, 4, 6 and 12 through 15 months of age. The first dose may be given as early as 6 weeks of age and the fourth dose may be given as late as 18 months of age.

"With today's approval of Menhibrix, there is now a combination vaccine that can be used to prevent potentially life-threatening Hib disease and two types of meningococcal disease in children. It is the first meningococcal vaccine that can be given starting as young as 6 weeks of age," Dr. Karen Midthun, director of the FDA's Center for Biologics Evaluation and Research, said in the news release.

The vaccine is made by GlaxoSmithKline Biologicals.

More information

The U.S. Centers for Disease Control and Prevention has more about meningococcal disease.

-- Robert Preidt

SOURCE: U.S. Food and Drug Administration, news release, June 14, 2012


'/>"/>
Copyright©2012 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. FDA Approves Generic Versions of Plavix
2. Combo Therapy May Help Ease Ringing in the Ears
3. Breast cancer clinical trial tests combo of heat shock protein inhibitor and hormonal therapy
4. Two-Drug Combo May Be Safe for Melanoma Treatment
5. Two-Drug Combo Helps Teens With Migraines
6. Value of Metformin, Insulin Combo for Type 2 Diabetes Questioned
7. Experimental Chemo Combo for Colon Cancer Disappoints
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
FDA Approves Combo Shot for Meningitis, Hib in Kids
(Date:5/23/2017)... Beach, CA (PRWEB) , ... May 23, 2017 ... ... Certified Facial Plastic and Reconstructive Surgeon Dr. Kevin Sadati, is pleased to announce ... interested in building collagen and elastin in their face, neck, and body through ...
(Date:5/23/2017)... Las Vegas, NV (PRWEB) , ... May 23, ... ... with Significance Dental Specialists, are educating patients on peri-implantitis in Las ... new patients to receive a custom gum disease consultation and leading care for ...
(Date:5/23/2017)... ... May 23, 2017 , ... Diagnotes, ... as a standard feature on its secure clinical communication platform. The platform allows ... video depending on the type and urgency of a situation. , “We ...
(Date:5/23/2017)... ... ... Orbita’s Nathan Treloar will discuss the role of voice-powered healthcare applications during a ... and IoT: Technology Innovators and Disruption , the workshop is part of Connections: ... consulting firm specializing in emerging consumer technology products and services. , Orbita, Inc. ...
(Date:5/23/2017)... , ... May 23, 2017 , ... ... receive treatment using the SPEED System™ Orthodontics, with or without a referral, from ... in El Segundo, CA, who is skilled in providing patients with the ...
Breaking Medicine News(10 mins):
(Date:5/22/2017)... , May 22, 2017  As the specialty ... whole continue to make the revolutionary shift from ... important for ensuring positive patient outcomes and shaping ... are shifting focus away from clinical trials and ... of long-term specialty drug therapy utilization in precise ...
(Date:5/15/2017)... , May 15, 2017  Amy Baxter MD, chief ... leader in noninvasive pain relief, was awarded a 2017 ... magazine. Baxter was recognized at the MM&M Top 40 ... York City on May 10, 2017. The ... biopharma industry go "beyond the pill."  "Innovation ...
(Date:5/11/2017)... TORONTO , May 11, 2017  Thornhill ... ) has been awarded an $8,049,024 USD five-year, ... Defense through the Canadian Commercial Corporation (CCC) ( ... Field Anesthesia Systems to administer general anesthesia to ... environment.  "The US Marine Corps have ...
Breaking Medicine Technology: